2024-517746-34-00RecruitingPhase 1
A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 28 Apr 2025
- Start date
- 26 Jun 2026
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Lung cancer, Metastatic breast cancer
- EU CT number
- 2024-517746-34-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 36
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced breast cancer or advanced non-small cell lung cancer (NSCLC) to test an imaging agent, [68Ga]Ga-DWJ155.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced breast cancer or advanced NSCLC.
Main reasons for not taking part
- Healthy volunteers cannot join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.